do glp 1 agonists cause pancreatic cancer GLP-1–Based Therapies: The Dilemma of Uncertainty Understanding GLP-1 receptor agonists and

Many people embarking on a weight management GLP-1 (Glucagon-like peptide-1) agonists often experience a mix of anticipation and frustration

Biomarker-driven personalization Matching the right drug to the right patient One of the most exciting developments is the use of biomarkers, measurable biological indicators, to predict how a patient will respond to therapy

The glucagon receptor activation drives hepatic fat oxidation in ways that dual agonists do not replicate

People with obesity or overweight (without T2DM) showed significant weight loss

These concerns are mainly based on rodent studies

detection of GLP-1R mRNA in situ hybridization